TLRY vs. CRON, USNA, CGC, MNMD, BTMD, SNDL, ACB, CDXC, FOMX, and MDWD
Should you be buying Tilray stock or one of its competitors? The main competitors of Tilray include Cronos Group (CRON), USANA Health Sciences (USNA), Canopy Growth (CGC), Mind Medicine (MindMed) (MNMD), biote (BTMD), SNDL (SNDL), Aurora Cannabis (ACB), ChromaDex (CDXC), Menlo Therapeutics (FOMX), and MediWound (MDWD).
Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, community ranking, media sentiment and dividends.
Tilray has a net margin of -43.98% compared to Tilray's net margin of -61.31%. Cronos Group's return on equity of -2.68% beat Tilray's return on equity.
8.7% of Cronos Group shares are held by institutional investors. Comparatively, 9.4% of Tilray shares are held by institutional investors. 6.9% of Cronos Group shares are held by company insiders. Comparatively, 0.7% of Tilray shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Cronos Group received 17 more outperform votes than Tilray when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 59.28% of users gave Tilray an outperform vote.
Cronos Group has higher earnings, but lower revenue than Tilray. Cronos Group is trading at a lower price-to-earnings ratio than Tilray, indicating that it is currently the more affordable of the two stocks.
In the previous week, Tilray had 6 more articles in the media than Cronos Group. MarketBeat recorded 9 mentions for Tilray and 3 mentions for Cronos Group. Tilray's average media sentiment score of 1.09 beat Cronos Group's score of 0.43 indicating that Cronos Group is being referred to more favorably in the media.
Cronos Group currently has a consensus price target of $3.00, suggesting a potential upside of 20.48%. Tilray has a consensus price target of $2.71, suggesting a potential upside of 52.15%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts clearly believe Tilray is more favorable than Cronos Group.
Cronos Group has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Tilray has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500.
Summary
Tilray beats Cronos Group on 11 of the 18 factors compared between the two stocks.
Get Tilray News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
